Amyloid PET imaging in multiple sclerosis: An 18F-florbetaben study

BMC Neurology

Volumn 15, Issue 1, 2015, Pages

  Matías Guiu, Jordi A ^a   Cabrera Martín, María Nieves ^a   Matías Guiu, Jorge ^a   Oreja Guevara, Celia ^a   Riola Parada, Cristina ^a   Moreno Ramos, Teresa ^a   Arrazola, Juan ^a   Carreras, José Luis ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Amyloid; Amyloid imaging; Multiple sclerosis; Myelin; Positron emission tomography; White matter

Indexed keywords

FLORBETAPIR F 18; 4-(N-METHYLAMINO)-4'-(2-(2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)STILBENE; AMYLOID; ANILINE DERIVATIVE; FLUORINE; STILBENE DERIVATIVE;

ADULT; ARTICLE; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; DEMYELINATING DISEASE; DIAGNOSTIC VALUE; DRUG UPTAKE; FEMALE; GRAY MATTER; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; POSITRON EMISSION TOMOGRAPHY; WHITE MATTER; WHITE MATTER INJURY; DIAGNOSTIC IMAGING; METABOLISM;

ADULT; AMYLOID; ANILINE COMPOUNDS; FEMALE; FLUORINE RADIOISOTOPES; GRAY MATTER; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; POSITRON-EMISSION TOMOGRAPHY; STILBENES; WHITE MATTER;

EID: 84947906867     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/s12883-015-0502-2     Document Type: Article

References (26)

1. Friese MA, Schattling B, Fugger L. Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat Rev Neurol. 2014;10:225-38.
2. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292-302.
3. De Stefano N, Airas L, Grigoriadis N, Mattle HP, O'Riordan J, Oreja-Guevara C, et al. Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs. 2014;28:147-56.
4. Rocchi L, Niccolini F, Politis M. Recent imaging advances in neurology. J Neurol. 2015;262:2182-94. doi: 10.1007/s00415-015-7711-x.
5. Baskin A, Giannakopoulos P, Ratib O, Seimbille Y, Assal F, Perani D, et al. PET radiotracers for molecular imaging in dementia. Curr Radiopharm. 2013;6:215-30.
6. Nasrallah IM, Wolk DA. Multimodality imaging of Alzheimer disease and other neurodegenerative dementias. J Nucl Med. 2014;55:2003-11.
7. Niccolini F, Su P, Politis M. PET in multiple sclerosis. Clin Nucl Med. 2015;40:e46-52.
8. Ciccarelli O, Barkhof F, Bodini B, De Stefano N, Golay X, Nicolay K, et al. Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging. Lancet Neurol. 2014;13:807-22.
9. Matthews PM, Datta G. Positron-emission tomography molecular imaging of glia and myelin in drug discovery for multiple sclerosis. Expert Opin Drug Discov. 2015;10:557-70.
10. Park E, Gallezot JD, Delgadillo A, Liu S, Planeta B, Lin SF, et al. (11)C-PBR28 imaging in multiple sclerosis patients and healthy controls: test-retest reproducibility and focal visualization of active white matter areas. Eur J Nucl Med Mol Imaging. 2015;42:1081-92.
11. Herholz K, Ebmeier K. Clinical amyloid imaging in Alzheimer's disease. Lancet Neurol. 2011;10:667-70.
12. Sabri O, Seibyl J, Rowe C, Barthel H. Beta-amyloid imaging with florbetaben. Clin Transl Imaging. 2015;3:13-26.
13. 11C]-2-(4'-methylaminophenyl)- 6-hydroxybenzothiazole. Ann Neurol. 2011;69:673-80.
14. Catafau AM, Bullich S. Amyloid PET imaging: applications beyond Alzheimer's disease. Clin Transl Imaging. 2015;3:39-55.
15. 11C]PIB for imaging myelin in the human brain: a test-retest reproducibility study in high-resolution research tomography. J Cereb Blood Flow Metab 2015. doi: 10.1038/jcbfm.2015.120.
16. Ashburner J, Friston KJ. Voxel-based morphometry--the methods. Neuroimage. 2000;11:805-21.
17. Battaglini M, Jenkinson M, De Stefano N. Evaluating and reducing the impact of white matter lesions on brain volume measurements. Hum Brain Mapp. 2012;33:2062-71.
18. Tzourio-Mazoyer N, Landeau D, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273-89.
19. Schmidt P, Gaser C, Arsic M, Buck D, Förschler A, Berthele A, et al. An automated tool for detection of FLAIR-hyperintense white-matter lesions in multiple sclerosis. Neuroimage. 2012;59:3774-83.
20. Bodini B, Veronese M, Garcia-Lorenzo D, Freeman L, Papeix C, Zalc B, et al. Positron emission tomography with [11C]-PIB: a clinically relevant tool for voxel-wise myelin quantification in multiple sclerosis. Mult Scler. 2013;19:174-5.
21. Madah DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015;14:183-93.
22. Sim FJ, Zhao C, Penderis J, Franklin RJM. The age-related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation. J Neurosci. 2002;22:2451-9.
23. Glodzik L, Kuceyeski A, Rusinek H, Tsui W, Mosconi L, Li Y, et al. Reduced glucose uptake and Aβ in brain regions with hyperintensities in connected white matter. Neuroimage. 2014;100:684-91.
24. Glodzik L, Rusinek H, Li J, Zhou C, Tsui W, Mosconi L, et al. Reduced retention of Pittsburgh compound B in white matter lesions. Eur J Nucl Med Mol Imaging. 2015;42:97-102.
25. Moll NM, Rietsch AM, Thomas S, Ransohoff AJ, Lee JC, Fox R, et al. Multiple sclerosis normal-appearing white matter: pathology-imaging considerations. Ann Neurol. 2011;70:764-73.
26. Colasanti A, Guo Q, Muhlert N, Giannetti P, Onega M, Newbould RD, et al. In vivo assessment of brain white matter inflammation in multiple sclerosis with (18)F-PBR111 PET. J Nucl Med. 2014;55:1112-8.